Al Harbi et al. [23] presented results of nivolumab, PD-1/PD-L1 axis inhibitor in pediatric glioblastoma patient resulting in a 60% reduction of GBM infiltration, improvement in clinical status, and continuous 10-month durable response [23]. The gene discussed is CD274; the disease is glioblastoma.